Trial Profile
A Double-Blind, Placebo-Controlled Study of RGH-188 (Cariprazine) in Bipolar Depression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Cariprazine (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- Sponsors Forest Laboratories
- 13 Feb 2020 Primary endpoint Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) has not been met as per results published in the International Clinical Psychopharmacology
- 13 Feb 2020 Results published in the International Clinical Psychopharmacology
- 30 Aug 2010 Preliminary top-line results have been reported in a Forest Laboratories media release.